Author Archives: Zinnia Jones

About Zinnia Jones

My work focuses on insights to be found across transgender sociology, public health, psychiatry, history of medicine, cognitive science, the social processes of science, transgender feminism, and human rights, taking an analytic approach that intersects these many perspectives and is guided by the lived experiences of transgender people. I live in Orlando with my family, and work mainly in technical writing.

Starting puberty blockers at the onset of puberty is standard care for trans youth. Starting HRT could be, too.

Disclaimer: I am not a medical professional and this is not medical advice. If a transgender or gender-questioning youth is experiencing the distress of gender dysphoria about changes to their growing body, when – if at all – should they … Continue reading

Posted in Biology of transition, Endocrinology, Media, Trans youth, Transgender medicine, Transphobia and prejudice | Tagged , , , , , , , , , , | Leave a comment

“Conveyer belt” fallacy against youth transition is missing a crucial piece: all the off-ramps before transitioning

Previously: Do all trans youth on puberty blockers go on to transition? (August 2017) Why gender-questioning youth continue or discontinue puberty blockers (March 2020) Anti-trans advocates have spent years attempting to popularize a folk notion of the process by which … Continue reading

Posted in Gender dysphoria, Hoaxes, Trans youth, Transphobia and prejudice | Tagged , , , , | Leave a comment

Second report of trans man undergoing successful fertility preservation without stopping testosterone – this time producing a viable embryo and live birth

Previously: Update on ovarian stimulation after testosterone use: Successful fertility preservation with less than a month’s interruption of HRT (April 2020) First report of trans man having successful fertility preservation without interrupting HRT (February 2021) Over the past few years, … Continue reading

Posted in Biology of transition, Endocrinology, Fertility and reproduction, Transmasculine | Tagged , , | Leave a comment

Additional data confirms 10mg of cyproterone acetate (CPA) is effective for testosterone suppression in trans women

Previously: Lower doses of cyproterone acetate may be similarly effective for blocking testosterone, with a lower risk of adverse effects (August 2020) Study of entire French population offers further data on cyproterone acetate and meningioma risk (February 2021) Disclaimer: I … Continue reading

Posted in Antiandrogens, Endocrinology, Oncology, Progestogens, Transgender medicine | Tagged , , | Leave a comment

Three decades and hundreds of transfeminine breast augmentations show rare regret and trends toward larger implants

Trans women and transfeminine people seeking breast augmentation as part of medical transition face certain concerns distinct from cis women who may receive this surgery. Our anatomical baseline is very different from that of adult cis women, with a recent … Continue reading

Posted in Breast, Oncology, Outcomes of transition, Surgery, Transfeminine, Transgender medicine | Tagged , | Leave a comment